Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Favipiravir for severe fever with thrombocytopenia syndrome
ChiCTR2000040089Phase 3Not yet recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of favipiravir in severe fever with thrombocytopenia syndrome (SFTS) and Bunyavirus infection (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: Fatality rate, Rate of severity and 2 more. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
favipiravir
03
Conditions
severe fever with thrombocytopenia syndrome (SFTS)Bunyavirus infection
Beyond the preview
Go deeper on ChiCTR2000040089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040089.